Stayble Therapeutics AB (“Stayble” or “the Company”) announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar disc herniation has been accepted for an oral presentation at the Annual Meeting of the International Society for the Study of the Lumbar Spine (ISSLS) in Atlanta, USA, May 12–16, 2025.
Stayble Therapeutics AB (“Stayble” or “the Company”) has interviewed Rachelle, a US Payer Expert about her view on the US market, challenges in the market and the potential of STA363.
Stayble Therapeutics AB (“Stayble” or “the Company”) has interviewed Jane Buus Laursen about her view from an experienced dealmaker’s perspective on STA363 and our coming partnering process.
Stayble Therapeutics AB (“Stayble” or “the Company”) today announces the intensification of its partnering activities with the company’s drug candidate STA363 in collaboration with a renowned transaction advisor. The company’s objective for the STA363 pain project is to identify a partner with the appropriate expertise and financial resources to advance the clinical development of STA363 towards commercialization.
In need of press photos? Contact us for a curated collection of images and logotypes approved for use in editorial purposes.
No events planned at the moment
Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.
Investors
